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Background. In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation 
of Ebola virus disease (EVD) in the United Kingdom. Vaccination was offered to 45 individuals with an initial assessment of high 
exposure risk.
Methods. Approval for rapid expanded access to the recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV) 
vaccine as an unlicensed emergency medicine was obtained from the relevant authorities. An observational follow-up study was car-
ried out for 1 year following vaccination.
Results. Twenty-six of 45 individuals elected to receive vaccination between 10 and 11 October 2015 following written informed 
consent. By day 14, 39% had seroconverted, increasing to 87% by day 28 and 100% by 3 months, although these responses were not 
always sustained. Neutralizing antibody responses were detectable in 36% by day 14 and 73% at 12 months. Common side effects 
included fatigue, myalgia, headache, arthralgia, and fever. These were positively associated with glycoprotein-specific T-cell but not 
immunoglobulin (Ig) M or IgG antibody responses. No severe vaccine-related adverse events were reported. No one exposed to the 
virus became infected.
Conclusions. This paper reports the use of the rVSV-ZEBOV vaccine given as an emergency intervention to individuals exposed 
to a patient presenting with a late reactivation of EVD. The vaccine was relatively well tolerated, but a high percentage developed a 
fever ≥37.5°C, necessitating urgent screening for Ebola virus, and a small number developed persistent arthralgia.
Keywords.  Ebola virus; rVSV-ZEBOV; vaccine; T cell.
The 2013–2016 Ebola virus (EBOV) outbreak in West Africa 
resulted in 28 646 reported cases of Ebola virus disease (EVD) 
and 11 323 deaths [1]. Healthcare workers were at particularly 
high risk of infection, with at least 500 deaths among 900 cases 
and amplified transmission of the disease in some healthcare 
settings. On 29 December 2014, a nurse who had worked in 
a treatment center in Sierra Leone was diagnosed with EVD 
on return to the United Kingdom [2]. Full protocols for the 
management of viral hemorrhagic fever were instituted imme-
diately. Of 3 individuals providing direct healthcare to the pa-
tient prior to transfer to the UK high-level isolation unit, none 
were categorized as high risk due to appropriate use of personal 
protective equipment (PPE). In contrast, when the same patient 
became unwell with a previously unreported complication of 
EVD reactivation associated with meningo-encephalitis be-
tween 5 and 9 October 2015 (the only reported late reactivation 
resulting in detectable viremia of 28 646 cases), 45 healthcare 
workers and household contacts were initially categorized as 
high risk. An incident management team (IMT) was set up in 
order to consider postexposure prophylaxis (PEP).
In October 2015, no licensed EBOV-PEP was available, al-
though vaccine responses had been shown to occur rapidly in 
macaques and humans. An interim phase III cluster-randomized 
trial of the replication competent recombinant vesicular stoma-
titis virus–Zaire Ebola virus (rVSV-ZEBOV) vaccine, published 
in July 2015, indicated 100% efficacy at 10 days postvaccination 
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and an acceptable side-effect profile [3]. In rhesus macaques, it 
was found to provide protection when given as early as 1 week 
prior to exposure [4] and had also been used successfully as 
PEP 49 hours after exposure in a laboratory worker following 
a high-titer needlestick injury [5]. Another 6 individuals sub-
sequently received the vaccine following exposure during the 
2013–2016 outbreak and none developed EVD [6].
In view of the evidence of a rapid immune response in vaccin-
ated individuals and the reported safety of the rVSV-ZEBOV vac-
cine, a decision was made to offer vaccination to those with the 
highest exposure risk. Vaccinated individuals were subsequently 
enrolled into the Glasgow Ebola Vaccine Follow-up Study (GEVS). 
Primary outcomes included evidence of infection with EBOV, the 
immune response following vaccination, and side effects.
METHODS
Approval Process
An international IMT including infection experts from Europe 
and the United States recommended that vaccination be offered 
to those with the highest exposure risk on 9 October 2015, 
following EVD diagnosis in the index case (Figure 1). Sixty-
five individuals were identified by the Greater Glasgow and 
Clyde public health team and designated as category 1, 2, or 3 
depending on their level of exposure following national guid-
ance (Supplementary Table 1). These cases were re-reviewed 
by 3 infectious diseases physicians, a public health physician, 
and a clinical virologist, incorporating additional expert risk 
categorization advice [7]. Those with a recent history of direct 
exposure to bodily fluids (vomit, diarrhea, blood, sweat, and/
or cerebrospinal fluid [CSF]) were recalled to an emergency 
vaccination clinic on 10–11 October. Twenty-six of 45 clinic at-
tendees accepted the offer of vaccination with informed consent 
under local National Health Service emergency regulations for 
unlicensed treatments (Figure 2). The following day, the West 
of Scotland Research Ethics Committee approved a prospective 
observational follow-up study (15/WS/0251).
Vaccination
The vaccine clinic was staffed by 6 doctors, 4 nurses, and a recep-
tionist. Any attendee with a temperature of 37.5°C or higher on 
arrival was immediately screened for EBOV by staff in full PPE 
(Tyvek suit, rubber boots, overshoes, FFP3 mask, visor, double 
gloves, and apron) (Supplementary Figure 1). Ebola virus poly-
merase chain reaction (PCR) was carried out within 6 hours of 
dispatch at Edinburgh Royal Infirmary. Vaccination protocols 
(Supplementary Information) [3] and rVSV-ZEBOV vaccine were 
provided by the World Health Organization (WHO) and main-
tained at −80 °C. A single dose of 2 × 107 plaque-forming units 
(pfu)/mL was prepared using the PREVAIL pharmacy manual [8] 
and administered intramuscularly in the deltoid muscle.
Clinical Follow-up
All individuals with a category 3 exposure were followed up with 
daily temperature screening for 3 weeks. Those with a tempera-
ture of 37.5°C or higher were tested for EBOV infection by reverse 
transcriptase (RT)–PCR. Vaccinated individuals were followed up 
at 30 minutes, 14 days, and 1, 3, 6, 9, and 12 months postvaccination. 
Figure 1. Timeline of exposure period and vaccine delivery. Following the recommendation to offer rVSV-ZEBOV vaccine by an expert panel, rapid approvals from the health 
board, MHRA, and local ethics committee were obtained. Abbreviations: CSF, cerebrospinal fluid; EBOV, Ebola virus; GG&C, Greater Glasgow and Clyde; MHRA, Medicines 
and Healthcare products Regulatory Agency; rVSV-ZEBOV, recombinant vesicular stomatitis virus–Zaire Ebola virus; WHO, World Health Organization; WoSREC, West of 
Scotland Research Ethics Committee.
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Twenty milliliters of blood, urine, and sputum samples and a semen 
sample from males were obtained at each clinic visit.
Laboratory Methods
Polymerase Chain Reaction
Samples obtained during fever and at days 14 and 28 following 
vaccination were tested at Edinburgh Royal Infirmary using an 
adapted version of the Trombley PCR assay [9]. Blood, urine, and 
semen were tested for the presence of the rVSV-ZEBOV vaccine 
using a vesicular stomatitis virus (VSV) RT-PCR [10]. Equine ar-
teritis virus was used as an internal control and had a detection 
limit of between 50 and 5 pfu/mL. Plasma, urine, sputum, serum, 
saliva, semen, and whole blood were extracted using the NucliSens 
EasyMAG (bioMérieux) according to the manufacturer’s instruc-
tions. Polymerase chain reaction was performed on 6 μL of RNA 
extract with the Platinum RT-PCR mastermix kit (Invitrogen) on 
an ABI Prism 7500 SDS real-time platform (Applied Biosystems) 
in a 15-μL reaction volume. The following thermal profile was 
used: 15 minutes at 50°C and then at 95°C for 15 minutes, fol-
lowed by 40 cycles of 95°C for 60 seconds and 60°C for 60 seconds.
Immunological Assays
Antibody assays were carried out at days 14 and 28 and at 3, 6, 9, 
and 12 months postvaccination, and T-cell responses measured 
by interferon (IFN) γ ELISpot and flow cytometry at 1, 3, 6, 9, 
and 12 months.
Enzyme-linked Immunosorbent Assay [11]
High-binding microtiter plates were coated with 1 µg/mL EBOV 
glycoprotein (GP) and incubated for 16–20 hours [11]. Following 
washing (phosphate-buffered saline/0.1% Tween20) and blocking 
(casein), 1:200 dilutions of plasma sample were added and incu-
bated for 2 hours. Polyclonal antihuman immunoglobulin (Ig) G–
AP antibody (1:1000) with substrate (diethanolamine substrate 
buffer with 20  mg p-Nitrophenyl Phosphate in 20  mL double 
distilled water) was used to develop the reaction. Optical density 
was determined at 405 nm. Samples were analyzed in duplicate, 
and background was subtracted from the mean of each sample. 
Plates were read using a predefined softmax template, which fits 
a 4-parameter logistic model to the dose-response data; IU/mL 
are based on the WHO International Reference Standard (NIBSC 
15/220), which was used to quantify the internal standard.
Neutralization Assays
Neutralization assays were performed at biosafety level 4 at the 
Institute of Virology, Philipps University Marburg, Germany, as 
previously described [12]. Volunteer blood plasma was incu-
bated at 56°C for 30 minutes for complement inactivation. After 
centrifugation at 13 000 rpm for 10 minutes, sera were serially 
diluted from 23–210in Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco) supplemented with 2% fetal calf serum (FCS; 
Gibco), penicillin (100 U/mL), streptomycin (100 mg/mL), and 
l-glutamine (2 mmol/L) (Invitrogen) in 96-well culture plates. 
One hundred Median Tissue Culture Infectious Dose (TCID50) 
units of EBOV (Zaire, isolate Mayinga, AF086833) were added 
to the serum dilutions. Following incubation at 37°C for 1 hour, 
Vero cell suspension in DMEM containing 2% FCS was added 
and incubated at 37°C with 5% CO2. Cytopathic effects were 
evaluated at 7 days postinfection. Neutralization titers were cal-
culated as geometric mean titer of 4 replicates.
IFNγ-ELISpot Assays
Peripheral blood mononuclear cells (PBMCs) were thawed 
using warm media and rested overnight at 37°C. The following 
day they were stimulated with overlapping EBOV GP peptides 
(MP1/MP2), as previously described [13]. Plates were counted 
using an S6 core analyzer (Cellular Technology Limited), and 
results adjusted to spot-forming units/1 × 106 cells/mL. Analysis 
required detection of a positive control, then subtraction of 
the non–peptide-stimulated control from peptide-stimulated 
samples.
T-cell Phenotyping Studies
Intracellular cytokine staining was performed as previously 
described [13]. Briefly, PBMCs were resuspended in warmed 
media and rested overnight at 37°C. The following day, cells were 
adjusted to 1 × 106 cells/mL in media containing anti-CD28, 
CD49d, and CD107a-PerCP cy5.5 (1 µg/mL). Cells were then 
untreated or stimulated with EBOV GP peptide pool, containing 
187 × 15-mer overlapping peptides at 2.5 µg/peptide or 1 µg/mL 
Staphylococcal Enterotoxin B peptide for 16–18 hours. After 2 
hours, brefeldin A and monensin (1 µg/mL) were added to block 
Figure 2. Selection of individuals for vaccination and follow-up study. Sixty-five 
contacts of the index patients were assessed by a team of healthcare specialists, 
45 of whom were asked to attend an outpatient follow-up clinic based on exposure 
risk. Of these, 26 received the rVSV-ZEBOV vaccine. Abbreviations: ID, infectious 
diseases; rVSV-ZEBOV, recombinant vesicular stomatitis virus–Zaire Ebola virus.
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cytokine secretion. The following day, samples were washed 
and LIVE/DEAD dye added. Samples were washed, incubated 
with cell surface antibodies (CD3-APC 750, CD4-BV786, 
CD8-AF700, CD19-BV510, and then CD14-BV510, CCR7-
APC, CD95-BV395, and CD45RO-BV605); then washed, fixed, 
and permeabilized; then stained for intracellular cytokines 
using IFNγ-AF488, TNFα-BV421, and IL-2-PE. Samples were 
analyzed using a BD Fortessa machine and FACS Diva, FlowJo, 
Pestle, and SPICE software (see Supplementary Information).
Statistical Analysis
Comparisons were made using parametric or nonparametric 
methods, as appropriate, using STATA version 10 (StataCorp).
RESULTS
Of 65 individuals designated as having had contact with the in-
fected patient, 45 category 3 contacts were found to have had 
possible direct skin contact with contaminated bodily fluids 
(vomit, sweat, blood, urine, or CSF). None had evidence of per-
cutaneous exposure and all would be categorized as “interme-
diate” in a more recently proposed exposure risk stratification 
[7]. Of these, 26 elected to receive vaccination following written 
informed consent and agreed to be followed as part of the ob-
servational GEVS. The median age of those vaccinated was 
40 years (range, 24–67 years). Fifteen of 26 (58%) were health-
care workers and 11 of 26 (42%) were household contacts. All 
individuals were followed up within the first 3 months following 
vaccination, but attendance at subsequent follow-up clinics was 
incomplete due to movement of medical and nursing staff to 
other cities within the United Kingdom (Supplementary Table 2). 
No one exposed to the virus became infected. All samples tested 
for EBOV and VSV were negative, including 2 febrile clinic at-
tendees tested for EBOV prior to vaccination.
Antibody Responses
IgG indirect enzyme-linked immunosorbent assay (ELISA) re-
sults are presented in Figure 3A as seroconversion (a positive 
antibody response at any time during the follow-up period) and 
individual responses detected at each follow-up visit to assess 
longevity of the response. By day 14, 39% had seroconverted. 
This increased to 87% by day 28 and 100% by 3 months. Such 
responses were not always sustained; one 68-year-old individual 
developed a positive IgG response at 14 days postvaccination, 
but the level descended below the detection threshold at all 
further time points (Supplementary Figure 2). This was not as-
sociated with the onset of any form of illness or immunosup-
pressive treatment during this time period. Detectable antibody 
responses fell to 73% by 12 months postvaccination. Individual 
results are shown in Supplementary Figure 3. A positive anti-GP 
IgM response peaked at 14–28 days postvaccination (Figure 3B) 
and negatively correlated with the emergence of neutralizing 
antibody responses (Supplementary Figure 4). Neutralizing 
antibody responses were detectable in 6 of 16 (36%) individuals 
by day 14 and peaked at 9–12 months postvaccination, with a 
detectable response in 9 of 12 individuals (73%) (Figure 3C).
T-cell Responses
IFNγ ELISpot responses to GP were detected at all time 
points, followed a similar pattern to neutralization over 
time (Supplementary Figure 5), and peaked at 6  months 
postvaccination (Figure 3D). Individual responses are shown in 
Supplementary Figure 6.
Side Effects
Side effects were common but mild in the majority of cases and 
were characterized by a syndrome of fatigue, myalgia, headache, 
and arthralgia (Tables 1 and 2). The presence of 1 symptom was 
strongly associated with the presence of others (Fisher’s exact 
test, P < .0001). During the first 72 hours of follow-up, 50% of 
individuals developed a fever of 37.5°C or higher, requiring 
in-hospital assessment and testing for EBOV. While the median 
duration of side effects was 0–1 days, a small number of patients 
developed long-standing symptoms of fatigue (up to 343 days), 
arthralgia (up to 261 days), and headache (up to 108 days). Two 
patients experienced long-lasting symptoms of arthralgia, one 
of whom had a diagnosis of osteoarthritis and flexor tendon-
itis thought to be unrelated to vaccination following specialist 
rheumatological review. Further details on cases of arthralgia 
are shown in Supplementary Table 3.
Symptoms of arthralgia, myalgia, and fatigue occurring at 
the time of sampling were significantly associated with a higher 
proportion of CD8+ IFNγ and CD4+ interleukin (IL) 2–se-
creting cells, while headache was associated with higher CD4+ 
IL2 (Figure 4) and IFNγ ELISpot response. No significant asso-
ciation with IgM, IgG, or neutralizing antibody responses was 
found (Supplementary Table 4).
DISCUSSION
The risk of transmission of EBOV to household contacts and 
healthcare workers exposed to infected bodily fluids is high, par-
ticularly prior to diagnosis when the risks may not be fully ap-
preciated. During the West Africa 2013–2016 outbreak, several 
infected individuals travelled by air to other countries, resulting 
in onward transmission. In Spain, a nurse became infected after 
caring for a patient transferred for specialist care, and in the 
United States, 2 nurses became infected after contact with an un-
diagnosed infected traveller. In Nigeria, 20 people were infected 
(11 healthcare workers) following a single introduction [14]. No 
randomized studies on the use of PEP have been carried out in 
humans, but vaccination and antiviral agents have been studied 
in exposed individuals on a case-by-case basis [6, 7] and more re-
cently in a large outbreak in the Democratic Republic of Congo.
The rVSV-ZEBOV vaccine is a highly effective vaccine 
that rapidly protects mice, hamsters, guinea pigs, nonhuman 
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primates, and humans from infection with EBOV when ad-
ministered prior to exposure. In humans, ring vaccination with 
rVSV-ZEBOV at a dose of 2 × 107 pfu was highly effective at 
preventing infection in contacts and contacts of contacts of in-
dividuals with EBOV infection in West Africa in a large phase 
III trial [15]. In this study, which initially involved an imme-
diate and a delayed vaccine arm, no infections occurred 10 days 
after vaccination in any recipient (100% vaccine efficacy). As 
a result, randomization was halted by an independent safety 
board and all subsequent participants in the study were offered 
immediate vaccination. Vaccination was carried out a median 
of 7.3 and 9.8 days following index patient symptom onset in 
the immediate and nonrandomized vaccine rings, respectively. 
Importantly, EBOV infection did occur in the 10-day period 
postvaccination, and this was not reduced compared with the 
delayed vaccination arm. This indicates that the timing of the 
Figure 3. Adaptive immune responses over time in vaccinated individuals. Antibody responses measured by indirect ELISA, IgM, neutralization, and IFNγ ELISpot are 
plotted over time. Anti-GP seroconversion rates are shown with a cutoff of 0.03 IU/mL (3 × standard deviation of negative control). For antibody assays, negative control 
levels from unvaccinated individuals are plotted with a positive QC (dotted bars). Bars show the geometric mean with 95% confidence interval. Numbers below the bars 
show the percentage of seroconverted people. Each dot is the average from 2 separate assays. For ELISpot, negative control represents unstimulated cells from vaccinated 
patients. P values < .05 (Mann-Whitney U test) are highlighted. A, Total anti-GP responses over time measured by indirect ELISA. B, Anti-GP IgM responses by ELISA over time. 
C, Neutralization responses over time. D, T-cell responses by IFNγ ELISpot to EBOV GP peptides over time. Abbreviations: D, day; EBOV, Ebola virus; ELISA, enzyme-linked 
immunosorbent assay; GP, glycoprotein; IFNγ, interferon γ; IgM, immunoglobulin M; M, months; Neut Ab, neutralizing antibodies; OD, optical density; QC, quality control.
Table 1. Side Effects Associated With rVSV-ZEBOV Vaccination Specified in the Follow-up Questionnaire
Side Effect Percentage (n/N)
Duration  
(IQR), days
Severity (1–5) 
(IQR), days Details
Fatigue 81 (21/26) 2 (1–5) 1 (1–2.5) …
Pain at injection site 69 (18/26) 2 (1–4) 1 (1–2) …
Myalgia 69 (18/26) 2.5 (1–4.5) 1 (1–2) …
Headache 69 (18/26) 2 (1–4) 1 (1–2) 38% reported migraines
Arthralgia 54 (14/26) 2.5 (1–17.75) 2 (1–2.75) Two patients with long-lasting symptoms
Fever (≥37.5°C) 50 (13/26) … … All tested negative for EBOV
Diarrhea 15 (4/26) 1 (1–1) 1 (1–1) …
Vomiting 8 (2/26) 18.5 (1–36) 2.5 (1–4) …
Induration 0 (0/26) 0 (0–0) 0 (0–0) …
Abbreviations: EBOV, Ebola virus; IQR, interquartile range; rVSV-ZEBOV, recombinant vesicular stomatitis virus–Zaire Ebola virus.
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use of the vaccine is likely to be critical and would need to stim-
ulate a protective immune response early within the median 9- 
to 10-day incubation period.
In rhesus macaques (in which infection is uniformly fatal 
with a more rapid onset of disease [6]), a single dose of the vac-
cine provides complete protection when given as few as 7 days 
before challenge [4, 16] and prevents infection in 50% when 
given as PEP 24 hours after infection [17]. Immunity is likely 
to be largely innate or antibody dependent as depletion of CD4 
or CD8+ cells postchallenge does not abrogate protection [18].
The first use of rVSV-ZEBOV in a human was reported in 
2011 following a high-titer needlestick exposure in a laboratory 
[5]. In this case, a single dose of 5 × 107 pfu was administered 
48 hours after the accident. At least 6 other individuals have 
now also received the vaccine, given 1–3  days postexposure, 
with the majority having been exposed in Ebola treatment 
units during the 2014–2016 West Africa outbreak [5, 19, 20]. 
All of these individuals were given a higher dose of vaccine and 
all developed significant side effects, although none became in-
fected (Table 3).
In this intervention, the 2 × 107–pfu dose was selected as a 
balance between very high levels of reactogenicity found with 
the 1 × 108–pfu dose and the lower immune responses found 
in individuals treated with lower doses in phase I and II studies 
[10, 12, 21]. We detected a higher incidence of symptoms in 
our study compared with these trials [10] but lower than that 
Table 2. Side Effects Associated With rVSV-ZEBOV Vaccination 
Volunteered During Follow-up
Other Reported Side Effects Percentage (n/N) Related to Vaccine
Ophthalmic shingles 3 (1/26) Possible
Fractured neck of femur 3 (1/26) Unrelated 
Dizziness 6 (2/26) Likely
Sinusitis 3 (1/26) Unrelated
Cervical lymphadenopathy 3 (1/26) Related (evaluated by  
ultrasound and too  
small for aspiration)
Abbreviation: rVSV-ZEBOV, recombinant vesicular stomatitis virus–Zaire Ebola virus.
Figure 4. Side effects related to T-cell response. CD4+ and CD8+ IFNγ and CD4+ IL2 responses in individuals with arthralgia (A), myalgia (B), fatigue (C), and headache (D) 
are shown. P values <.05 (Mann-Whitney U test) are highlighted. Abbreviations: IFNγ, interferon γ; IL2, interleukin 2.
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found in the cases described in Table 3. The high incidence of 
symptoms may be related to variation in genetic background 
and high levels of psychological stress.
The risk of infection was likely to have been highest in those 
who had contact with body fluids from the index case. While 
blood and CSF tested positive by PCR, infectious virus was only 
isolated from the CSF where the titer was highest [2] (vomit, 
urine, saliva, and rectal swabs all subsequently tested PCR nega-
tive). In retrospect, the individuals with the highest potential risk 
of transmission were those exposed to CSF during the lumbar 
puncture procedure that took place 3 days before vaccination.
The mechanism of protection following vaccination with 
rVSV-ZEBOV may involve innate, T-cell–mediated, and/or 
B-cell–mediated responses [15, 22, 23]. We assessed the im-
mune response by indirect ELISA, neutralization with live 
ZEBOV (Mayinga strain), ELISpot, and flow cytometry. There 
are no definite surrogates of immunity, but such responses have 
been associated with protection from infection in macaques and 
humans. IgM responses peaked at day 14, while IgG serocon-
version occurred in 39% at 14 days postvaccination, increasing 
to 87% by day 28 and to 100% of individuals by 3  months. 
The day 14 anti-GP seroconversion was lower than that found 
in rhesus macaques [4, 24, 25] and in human participants in 
pooled North American phase I  studies, which showed uni-
versal seroconversion by day 14 [26]. In the phase II PREVAIL 
trials, 77–83% of 500 individuals seroconverted within 1 month 
of vaccination [8, 27]. We found that the numbers of individuals 
with positive neutralizing antibody responses were similar to 
those with anti-GP responses evaluated by ELISA. Seventy-five 
percent of individuals were anti–GP positive at 1 year after vac-
cination and 73% had positive neutralization results. This is in 
keeping with a long-lasting effect found in other studies [28]. 
T-cell responses directed against GP were also detected, as de-
scribed previously [23].
Future use of rVSV-ZEBOV vaccine must be balanced 
against the risk of side effects. It is a live vaccine, and fever in 
vaccinated individuals has been found to be associated with ev-
idence of replicating rVSV-ZEBOV in blood [29]. The side-effect 
profile of these Scottish vaccine recipients was similar to recipients 
in Switzerland with a higher prevalence of arthralgia than reported 
in phase I studies in Germany and Kenya. Arthralgia in Swiss par-
ticipants lasted a median of 8 days (range, 3–167 days; interquartile 
range, 4–87 days) [12]. As in this study, symptoms were generally 
short lived but were longer lasting in 2 patients. Headache, fatigue, 
myalgia, and arthralgia were associated with the magnitude of 
T-cell response to pooled GP peptides, with higher CD4+ produc-
tion of IL2 and CD8+ production of IFNγ, but not with antibody 
responses.
There were several limitations to this study. First, we cannot 
comment on efficacy of the vaccine as this was not a random-
ized controlled intervention following definitive virus exposure. 
However, we have demonstrated that Ebola vaccine used as PEP 
was immunogenic and relatively well tolerated. Timing of ad-
ministration is likely to be critical as some individuals did not 
develop a rapid immune response. While vaccination is a rea-
sonable PEP strategy, other interventions such as the use of an-
tiviral agents or newer vaccines may be warranted.
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